News – Page 2 – www.brainwork.md

18th February 2019

FDA issues warnings on illegal Alzheimer’s drugs

https://www.brainwork.md/content/uploads/2019/02/Brainwork-FDAWarns.jpg 2880 1920 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 18th February 2019 18th February 2019

On 11 February 2019, the United States Food and Drug Administration (FDA) issued warnings to 17 companies that illegally sold more than 50 products claiming to prevent, treat or cure…

Peter Stevenson, PhD
0
0

31st January 2019

Stem-cell therapy puts the brakes on MS

https://www.brainwork.md/content/uploads/2019/01/Brainwork-StemCellStopMS.jpg 2850 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 31st January 2019 1st February 2019

New data reveal the power of stem-cell transplantation in slowing or even halting disease progression in patients with RRMS, thereby reinvigorating further exploration of cellular treatments in MS. The findings…

Peter Stevenson, PhD
0
0

25th January 2019

‘Leaky’ blood vessels linked to Alzheimer’s

https://www.brainwork.md/content/uploads/2019/01/luis-tosta-266667-unsplash.jpg 3500 2333 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 25th January 2019 1st February 2019

Leaky blood vessels in the brain appear to be a driver of cognitive dysfunction in Alzheimer’s disease, a new study reports. The research, published in Nature Medicine, followed 161 older…

Peter Stevenson, PhD
0
1

18th January 2019

Acting fast on atrial fibrillation

https://www.brainwork.md/content/uploads/2019/01/Brainwork-ActingFast.jpg 2800 2100 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 18th January 2019 1st February 2019

Early detection of atrial fibrillation – the next breakthrough in health and wearable technology? Johnson & Johnson, in collaboration with Apple Inc., just announced plans to investigate the use of…

Carlotta Foletti, PhD
0
0

30th November 2018

Gene therapy shows promise in Parkinson’s disease

https://www.brainwork.md/content/uploads/2018/11/Brainwork-ParkinsonsPromise.jpg 2100 1400 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 30th November 2018 30th November 2018

Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…

Mea Holm, PhD
0
0

29th October 2018

Herpes and Alzheimer’s: Trigger or symptom?

https://www.brainwork.md/content/uploads/2018/10/Brainwork-Herpes.jpg 1920 1280 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 29th October 2018 29th October 2018

A new review article, published in Frontiers in Aging Neuroscience, has offered fresh evidence in support of a link between the Herpes Simplex Virus 1 (HSV1) and Alzheimer’s disease (AD).…

Peter Stevenson, PhD
0
0

19th October 2018

Cognitive impairment in MS

https://www.brainwork.md/content/uploads/2018/10/Brainwork-MSCognitive_2048-1.jpg 2048 1153 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 19th October 2018 1st February 2019

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

Mea Holm, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
1
0

15th October 2018

Results from the MS-SMART trial unveiled

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMSSMART.jpg 3971 2975 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 15th October 2018 15th October 2018

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

Mea Holm, PhD
0
0

15th October 2018

De-risking PML: A conversation with Prof. Walter Atwood

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMS-Outside.jpg 2872 2598 Prof. Dr. Krassen Nedeltchev Prof. Dr. Krassen Nedeltchev https://secure.gravatar.com/avatar/aaadc696c1b66fe476051e7e4012d01a?s=96&d=mm&r=g 15th October 2018 23rd October 2018

We interviewed Professor Walter Atwood last week at the 2018 ECTRIMS congress in Berlin, Germany, to learn about advances in treating progressive multifocal leukoencephalopathy (PML) – an important treatment-associated infection…

Prof. Dr. Krassen Nedeltchev
0
1